» Articles » PMID: 2750731

Human Teratogens, Prenatal Mortality, and Selection Bias

Overview
Journal Am J Epidemiol
Specialty Public Health
Date 1989 Aug 1
PMID 2750731
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Etiologic inferences on human teratogens are usually derived from case-control studies conducted either at birth or in spontaneous abortion series. Because both teratogens and defects may be associated with an increased risk of prenatal mortality, the possibility exists that selection bias may affect etiologic inferences. The authors derive relations between the true odds ratio (OR) relating a teratogen and a defect at the time of the occurrence of the defect and the apparent odds ratios observed in spontaneous abortion series and at birth, as functions of prenatal mortality. Depending on the pattern of interaction between the teratogen and the defect in affecting the rate of prenatal mortality, selection bias may lead to overestimation or underestimation of the true odds ratio. With increasing multiplicative effects on prenatal mortality, changes in selection bias tend to increase the observed odds ratio in spontaneous abortion series but to decrease the observed odds ratio at birth. For a range of rates of prenatal mortality, weak associations between exposures and defects (OR = 0.3-3) may well be due to selection bias; conversely, weak teratogens (OR less than 3) may be missed in case-control studies of defects conducted at birth. Selection bias due to prenatal mortality must be considered in the interpretation of etiologic studies of birth defects.

Citing Articles

Association between maternal mRNA covid-19 vaccination in early pregnancy and major congenital anomalies in offspring: population based cohort study with sibling matched analysis.

Jorgensen S, Drover S, Fell D, Austin P, DSouza R, Guttmann A BMJ Med. 2024; 3(1):e000743.

PMID: 39574424 PMC: 11579536. DOI: 10.1136/bmjmed-2023-000743.


Characterizing Fit-for-Purpose Real-World Data: An Assessment of a Mother-Infant Linkage in the Japan Medical Data Center Claims Database.

Barberio J, Hernandez R, Naimi A, Patzer R, Kim C, Lash T Clin Epidemiol. 2024; 16:31-43.

PMID: 38313043 PMC: 10838663. DOI: 10.2147/CLEP.S429246.


Maternal and fetal outcomes following exposure to duloxetine in pregnancy: cohort study.

Huybrechts K, Bateman B, Pawar A, Bessette L, Mogun H, Levin R BMJ. 2020; 368:m237.

PMID: 32075794 PMC: 7190016. DOI: 10.1136/bmj.m237.


Use of real-world evidence from healthcare utilization data to evaluate drug safety during pregnancy.

Huybrechts K, Bateman B, Hernandez-Diaz S Pharmacoepidemiol Drug Saf. 2019; 28(7):906-922.

PMID: 31074570 PMC: 6823105. DOI: 10.1002/pds.4789.


Association Between Methylphenidate and Amphetamine Use in Pregnancy and Risk of Congenital Malformations: A Cohort Study From the International Pregnancy Safety Study Consortium.

Huybrechts K, Broms G, Christensen L, Einarsdottir K, Engeland A, Furu K JAMA Psychiatry. 2017; 75(2):167-175.

PMID: 29238795 PMC: 5838573. DOI: 10.1001/jamapsychiatry.2017.3644.